BVS Bioventus Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1665988 · Fiscal year ends 12/31
Financial factors as of 2026-09-26 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY3.9%
TTM net income YoY655.0%
TTM EPS YoY575.0%
Revenue 3-yr CAGR5.2%
Net income 3-yr CAGR—
Margins
Gross margin68.7%
Operating margin9.7%
Net margin9.8%
FCF margin14.5%
EBITDA margin14.0%
Returns
ROE28.2%
ROA8.3%
ROIC (approx.)12.8%
Asset turnover0.85x
Leverage & solvency
Liabilities / assets56.7%
Debt / equity0.96x
Current ratio1.68x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.53x
Accruals ratio-4.4%
Payout ratio—
Capex / revenue0.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-26 | 2026Q22026-06-27 | 2026Q12026-03-28 | 2025Q4*2025-12-31 | 2025Q32025-09-27 | 2025Q22025-06-28 | 2025Q12025-03-29 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $142.44M | $153.21M | $132.09M | $157.90M | $138.65M | $147.66M | $123.88M | $153.64M |
| Cost of revenue | $45.31M | $47.54M | $41.32M | $49.12M | $44.42M | $45.57M | $40.82M | $50.99M |
| Gross profit | $97.13M | $105.67M | $90.77M | $108.78M | $94.23M | $102.09M | $83.06M | $102.66M |
| R&D expense | $3.44M | $3.17M | $2.47M | $3.01M | $2.92M | $3.17M | $3.01M | $3.27M |
| SG&A expense | $82.94M | $82.74M | $78.33M | $82.76M | $78.66M | $79.11M | $73.50M | $86.87M |
| Operating income | $9.70M | $19.13M | $8.42M | $19.49M | $11.25M | $18.37M | $4.87M | $7.70M |
| Pretax income | $6.16M | $15.31M | $4.52M | $14.14M | $4.67M | $10.31M | -$3.42M | -$53,000 |
| Income tax | -$701,000 | -$20.90M | $571,000 | -$3.17M | $664,000 | $1.04M | -$95,000 | $550,000 |
| Net income | $5.99M | $33.44M | $3.11M | $14.76M | $3.15M | $7.46M | -$2.64M | -$388,000 |
| EBITDA | $10.75M | $20.17M | $19.62M | $31.18M | $12.65M | $19.81M | $16.73M | $20.11M |
| EPS (basic) | 0.09 | 0.49 | 0.05 | — | 0.05 | 0.11 | -0.04 | — |
| EPS (diluted) | 0.08 | 0.47 | 0.04 | — | 0.05 | 0.11 | -0.04 | — |
| Weighted avg. shares (diluted) | 72.49M | 70.84M | 70.01M | — | 68.84M | 68.54M | 66.01M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $30.71M | $29.46M | $35.85M | $51.24M | $42.16M | $32.91M | $22.80M | $41.58M |
| Receivables | $138.23M | $138.41M | $120.53M | $128.30M | $130.40M | $132.37M | $118.08M | $127.39M |
| Inventory | $83.10M | $79.81M | $83.19M | $82.24M | $96.27M | $96.47M | $94.05M | $92.47M |
| Current assets | $265.54M | $257.53M | $249.81M | $272.84M | $280.90M | $275.20M | $249.37M | $275.61M |
| PP&E, net | $19.78M | $20.53M | $21.29M | $21.90M | $22.98M | $24.51M | $25.72M | $27.01M |
| Goodwill | $7.46M | $7.46M | $7.46M | $7.46M | $7.46M | $7.46M | $7.46M | $7.46M |
| Intangibles | $343.93M | $351.05M | $359.66M | $368.42M | $377.40M | $386.95M | $395.73M | $404.73M |
| Total assets | $673.43M | $673.35M | $650.54M | $683.56M | $701.59M | $706.79M | $691.41M | $727.96M |
| Current liabilities | $157.70M | $152.45M | $148.09M | $160.38M | $161.75M | $185.68M | $174.75M | $210.40M |
| Short-term debt | $18.75M | $18.75M | $18.75M | $15.00M | $11.25M | $43.36M | $37.34M | $27.34M |
| Long-term debt | $211.08M | $229.70M | $253.33M | $278.95M | $311.33M | $297.88M | $308.59M | $308.29M |
| Total debt | $229.83M | $248.45M | $272.08M | $293.95M | $322.58M | $341.24M | $345.93M | $335.63M |
| Total liabilities | $381.56M | $395.93M | $416.27M | $455.11M | $494.34M | $505.49M | $505.94M | $542.35M |
| Shareholders' equity | $240.50M | $228.31M | $188.90M | $184.10M | $166.10M | $161.24M | $148.14M | $147.94M |
| Net debt | $199.12M | $219.00M | $236.23M | $242.71M | $280.42M | $308.33M | $323.13M | $294.05M |
| Cash flow statement | ||||||||
| Operating cash flow | $20.66M | $19.87M | $8.93M | $37.97M | $30.10M | $25.94M | -$19.33M | $19.32M |
| Capital expenditure | $334,000 | $960,000 | $574,000 | $580,000 | $473,000 | $683,000 | $826,000 | $574,000 |
| Free cash flow | $20.32M | $18.91M | $8.36M | $37.39M | $29.62M | $25.25M | -$20.16M | $18.75M |
| Investing cash flow | -$1.83M | -$2.46M | -$574,000 | -$580,000 | -$473,000 | -$1.37M | -$826,000 | $24.10M |
| Financing cash flow | -$17.58M | -$23.43M | -$23.14M | -$28.45M | -$19.98M | -$14.66M | $947,000 | -$42.85M |
| Depreciation & amortization | $1.05M | $1.04M | $11.21M | $11.69M | $1.40M | $1.44M | $11.87M | $12.40M |
| Stock-based compensation | $4.76M | $4.77M | $3.26M | $3.44M | $3.18M | $3.36M | $2.41M | $2.02M |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.